Opinion
A sports device to ‘protect the brain’ illustrates a major problem with the FDA de novo pathway
This is not just about one device. It’s about what happens when institutions grow comfortable living in their own ambiguity and hiding behind opacity.” ...
For banks navigating increasingly complex regulatory environments, the framework offers a path toward operational efficiency without compromising adherence standards.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback